Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized placebo-controlled venetoclax plus induction and consolidation chemotherapy in newly diagnosed AML or MDS-EB2
2023-507518-28-00Phase 3Authorised
- Sponsor
- University Hospital Ulm
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 3, randomised trial in acute myeloid leukemia (AML) and myelodysplastic syndrome with excess blasts (MDS-EB) comparing Venetoclax arm with Placebo arm (2 arms). Primary endpoint: Event-free survival. Planned start Sep 2022; status: authorised.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome with excess blasts (MDS-EB)
Beyond the preview
Go deeper on 2023-507518-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507518-28-00.